BMC cancer · 2025
Plasma cfDNA multi-omic biomarkers profiling for detection and stratification of gastric carcinoma.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Song Shiyi, Zhang Xiuli, Cui Pin, He Weihuang, Zhou Jiyuan, Wang Shubing, Xiong Yong, Xu Shu, Lin Xiaohui, Huang Guozeng, Tan Xiaohua, Xu Qinglong, Liu Yongling, Li Qingqun, Yuan Kehua, Feng Mingji, Lai Hanming, Yang Hui, Zhang Shaorong
Аннотация
Despite being the third in death rate among all cancers globally, gastric carcinoma (GC) is far from being detected accurately and timely, which could benefit the prognosis. To achieve this, we performed whole-genome sequencing (WGS) to plasma cfDNA of 733 participants, including healthy individuals, patients with benign gastric diseases and GC patients. The multi-omic biomarkers in this study, including fragmentation profile, end motif and genome-wide Copy Number Variations (CNV) of plasma cfDNA, are recently developed means for cancer detection and monitoring. And these biomarkers were extracted from WGS data to build machine learning algorithm based classifiers, prediction models, to discriminate GC patients from healthy individuals, achieving extremely high precision of sensitivity at 94.87% and specificity at 99.35%. Therefore, these cfDNA multi-omic biomarkers may serve as means to detect GC accurately, affordably and timely.